G-NiiB Immunity Pro 28 sachets
An extra potent probiotic formula, clinically proven to rebalance your gut microbiome and improve immune function. Based on the world’s first study on the gut microbiome of covid patients researched and endorsed by the CUHK.
Pack size: 28 sachets.
Created by CUHK, G-Niib Pro rebalances your gut microbiome, correcting dysbiosis which occurs when bad bacteria in your gut outweigh the good. Dysbiosis is linked to more severe symptoms of cold and flu as well as long-term effects. It is also a key signifier of low immunity. Research shows that 40% of the HK population experience moderate to severe dysbiosis.
This probiotic helps reduce symptoms of colds and flu, as well as protecting you from contracting colds.
G-Niib features 10 billion CFU from 3 prebiotic and 3 probiotic strains, among which is bifidobacterium adolescentis. Studies show that up to 85% of healthy Hong Kongers could have either low or absent levels of b. adolescentis.
G-Niib offers therapeutic support for your gut microbiome, rebalancing the good bacteria in your gut for better immune defence.
Due to its strength, this clinical grade probiotic is only available via prescription from naturopaths in-clinic.
You can buy G-Niib Pro’s sister product, G-Niib Plus online.
One sachet daily or as directed by healthcare professional. Sprinkle in water, non-frizzy or non-alcoholic drinks, or food (below 45C). Can be taken at any time of the day but best consumed with a meal.
Galactooligosaccharides,. Xylooligosaccharide, Resistant dextrin, Probiotics Blend (3 Bifidobacteria, including Bifidobacterium adolescentis, 10 billion CFU/sachet).
G-NiiB® is the registered trademark of GenieBiome Limited.
GenieBiome, a biotechnology spinout from The Chinese University of Hong Kong was founded by world-renowned clinician-scientists and supported by a multidisciplinary team of experts in microbiology, metagenomics, bioinformatics, disease biomarkers, food technology, clinical trials, IP development and commercialization. For over a decade, our team has pioneered the use of microbiome with evidence-based science to tackle a myriad of diseases, including COVID-19, colorectal cancer, obesity, eczema, and autism.
Our precision portfolio of G-NiiB includes diagnostic and risk prediction tests, next-generation microbiome precision formula, and precision medicine tailored for the Asian population.
"G-NiiB immunity formula developed from the first global Covid-19 microbiome research findings, and the first in the world microbiome based non-invasive colorectal cancer diagnostic are ready to serve the Asian Chinese population now."